| Register
| Log out
Submit An Article

Zilosul

Latest Articles

  • Paradigm eyes FDA and TGA submission as patient data confirms major joint pain reduction

    Paradigm eyes FDA and TGA submission as patient data confirms major joint pain reduction

    Clinical data trials being conducted by Paradigm Biopharmaceuticals (ASX: PAR) continue to deliver impressive patient outcomes for sufferers of chronic joint pain and osteoarthritis with 13 new patients having joined the trials and reported significantly better quality of life upon treatment with Zilosul. The most recent round of trials have been conducted in Australia under

    Read More
    Public
  • Retired NFL players endorse Zilosul, Paradigm’s osteoarthritis drug trials

    Retired NFL players endorse Zilosul, Paradigm’s osteoarthritis drug trials

    Professional athletes may soon have a new treatment for knee osteoarthritis after Paradigm Biopharmaceuticals (ASX: PAR) received glowing endorsements from two former NFL players undergoing the current round of Zilosul® treatment trials.  The trials of Zilosul® have been conducted on ten patients suffering from varying degrees of knee osteoarthritis under the Food and Drug Administration’s

    Read More
    Public
  • Paradigm clinical trial results identify breakthrough in fight against osteoarthritis

    Paradigm clinical trial results identify breakthrough in fight against osteoarthritis

    Osteoarthritis sufferers could soon receive effective pain relief and reduced onset from the degenerative disease after Paradigm Biopharmaceuticals (ASX: PAR) reported breakthrough clinical trial results which identified a significant reduction of pain levels from participants using their Zilosul product.  The 53-day clinical trial saw testing of the injectable Pentosan-based treatment (iPPS) which demonstrated a conclusive

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.